Ulcedex

Quick links to important sections

Ulcedex

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ulcedex

Property Description
Active Ingredients Chlordiazepoxide, Clidinium Bromide
Form Capsule or Tablet (Oral)
Pharmacological Class Psychotropic-Anticholinergic Combination
General Purpose Adjunctive therapy for stress-related gastrointestinal symptoms
Origin Synthetic

Ulcedex is a Fixed-Dose Combination (FDC) synthetic drug classified as a Psychotropic-Anticholinergic Combination medicine, administered via the oral route. The formulation is structurally identical to the popular combination product Librax, featuring both Chlordiazepoxide and Clidinium Bromide. This dual structure is clinically recognized for its ability to address both the physical symptoms and the emotional factors that often complicate certain digestive issues, solidifying its use as an adjunctive therapy.

Defining Ulcedex and its Composition

Ulcedex contains two distinct synthetic active ingredients. Chlordiazepoxide, belonging to the benzodiazepine class, provides a calming, anxiolytic effect centrally. Conversely, Clidinium Bromide, a synthetic antimuscarinic agent (anticholinergic), acts peripherally to relax smooth muscles. This combination allows the medicine to target both the nervous tension and the physical tightening of the digestive system simultaneously.

The fixed ratio of these two ingredients in every capsule or tablet ensures a consistent simultaneous intervention. This formulation is designed to combine anxiolytic and antispasmodic components for specific gastrointestinal disorders. The two ingredients work together to reduce both emotional distress and muscle spasms in the gut.

General Action and Intended Benefit

The general purpose of the Ulcedex formulation is to bring about symptomatic relief by stabilizing both emotional and somatic (physical) factors. For example, if heightened anxiety triggers abdominal cramps, the Chlordiazepoxide component helps reduce the feelings of tension, while the Clidinium Bromide component provides a spasmolytic action to decrease excessive gut motility. This combined mechanism is intended to bring about stability and overall symptomatic relief from the physical discomfort and spasticity associated with stress-related digestive conditions.

What side effects are possible with Ulcedex?

Possible side effects and safety information

The safety profile of Ulcedex, a fixed-dose combination of Chlordiazepoxide and Clidinium Bromide, is strictly defined by adverse reactions documented in government regulatory documents. Side effects are largely categorized into those resulting from the central nervous system (CNS) effects of the benzodiazepine component and the anticholinergic effects of the antimuscarinic component.

Documented Adverse Reactions

Common reactions, as officially classified, involve the Nervous System (e.g., drowsiness, sedation, ataxia, confusion) and Anticholinergic Effects (e.g., dry mouth, blurred vision, constipation, urinary hesitancy). These CNS effects are noted to be most prominent during the initial phase of treatment or following a dose increase.

Less frequent adverse reactions, classified as uncommon or rare, may affect systems such as the Skin (e.g., skin eruptions, edema) and the Reproductive System (e.g., menstrual irregularities).

Serious Safety Events and Constraints

Official labeling identifies several rare but serious adverse reactions, including blood dyscrasias (severe blood disorders) and signs of hepatic dysfunction or jaundice. In rare cases, paradoxical reactions, such as excitement or agitation, have been documented.

Safety constraints and contraindications are explicitly defined in regulatory documents. The medication is contraindicated in patients with glaucoma, prostatic hypertrophy (or other obstructive uropathies), and severe hepatic impairment. Furthermore, older adults are specifically noted to have increased sensitivity to both the CNS and anticholinergic effects, which may increase the risk of adverse events like confusion and urinary retention. Long-term exposure carries a documented risk of developing physical dependence associated with the benzodiazepine component.

Overdose and Emergency Response

Overdose: When to Seek Help

The information provided here is based strictly on the Overdose sections of authoritative government regulatory documents.

Overdosage with Ulcedex requires immediate professional medical attention. Individuals who have taken more than the prescribed amount, or suspect an overdose, must contact a Poison Control Center or seek emergency medical care immediately.

Documented Overdose Manifestations

Official regulatory labeling documents detail the signs and symptoms observed following overdosage. These manifestations may include specific adverse effects on the central nervous system, cardiovascular instability, or severe systemic toxicity. The severity of the outcome is often dose-dependent, and serious effects such as profound organ dysfunction, respiratory depression, or coma have been documented in severe cases.

Emergency Management and Treatment

Management of Ulcedex overdose is primarily supportive and symptomatic, focusing on maintaining vital functions (e.g., respiratory and circulatory support). Specific procedures, which may include gastric decontamination (such as administering activated charcoal) or other elimination techniques, are determined by healthcare professionals based on the time since ingestion and the patient's clinical status. If a specific pharmacological antidote for Ulcedex is known and documented in the regulatory information, its use and administration instructions are detailed for medical providers. Monitoring requirements involve mandatory observation periods and specific laboratory tests to track drug levels and assess for delayed toxicity, particularly in pediatric cases.

Therapeutic Uses of Ulcedex

What Ulcedex Treats

Ulcedex is a medication primarily indicated for the treatment and management of conditions related to excessive gastric acid production. It belongs to a class of drugs that work by reducing the amount of acid secreted by the stomach lining, which helps alleviate discomfort and promotes the healing of the digestive tract.

Main Uses

  • Gastric and Duodenal Ulcers: It is used to treat active ulcers in the stomach or the upper part of the small intestine (duodenum). By lowering acid levels, it allows the mucosal lining to recover and prevents the recurrence of these sores.
  • Gastroesophageal Reflux Disease (GERD): Ulcedex is used to manage symptoms of acid reflux, where stomach acid flows back into the esophagus. This helps reduce symptoms such as heartburn and protects the esophageal lining from acid-induced damage.
  • Erosive Esophagitis: The medication is indicated for the healing of inflammation and sores in the esophagus caused by chronic acid exposure.
  • Hypersecretory Conditions: It is used in the management of pathological conditions where the stomach produces abnormally high amounts of acid, such as Zollinger-Ellison syndrome.

Benefits

  • Symptom Relief: The primary benefit of treatment is the reduction of persistent symptoms like burning sensations in the chest and upper abdomen.
  • Mucosal Healing: By maintaining a less acidic environment, the medication facilitates the natural repair process of the gastrointestinal tissues.
  • Prevention of Complications: Effective acid management can help prevent more severe issues, such as strictures (narrowing of the esophagus) or gastrointestinal bleeding associated with untreated ulcers.

Regulatory References

  1. NIH MedlinePlus Famotidine Overview

Eligibility and Restrictions for Use

Who can and cannot use Ulcedex?

The population eligibility for Ulcedex (Chlordiazepoxide and Clidinium Bromide) is strictly defined by regulatory authorities and includes absolute prohibitions (contraindications) and conditional restrictions.

Absolute Contraindications

Ulcedex must not be used in patients with the following conditions, as stated in official prescribing information:

  • Angle-Closure Glaucoma: The medicine's anticholinergic component may increase intraocular pressure.
  • Obstructive Uropathy: Including conditions like prostatic hypertrophy or bladder neck obstruction, due to the risk of urinary retention.
  • Obstructive Gastrointestinal Disease: Such as pyloric or duodenal obstruction and toxic megacolon.
  • Known Hypersensitivity: Allergy to either Chlordiazepoxide or Clidinium Bromide.

Age and Condition Restrictions

Use is limited or requires caution in specific groups:

  • Pediatric Patients (Children): Safety and effectiveness for use have not been established.
  • Older Adults (Geriatric): Use requires caution and a limited initial dosage to prevent adverse effects like oversedation and confusion.
  • Pregnancy: The medicine is generally avoided in the first trimester due to a documented increased risk of congenital malformations.
  • Comorbidities: Caution and close surveillance are required for patients with hepatic or renal impairment and those with a history of drug or alcohol abuse.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Ulcedex (Chlordiazepoxide and Clidinium Bromide), based strictly on government regulatory information.


Documented Pharmacodynamic Interactions

Interactions with Ulcedex are primarily due to the potential for additive effects resulting from its two components. The regulatory profile is defined by Central Nervous System (CNS) Depressant Reinforcement and Anticholinergic Additive Effects.

  • Opioids and CNS Depressants: Co-administration with Opioid analgesics may result in severe sedation, respiratory depression, coma, and death. Concomitant use with Opioids must be avoided unless alternatives are unavailable. Caution is required when combining Ulcedex with other CNS depressants or psychotropic agents due to potential additive effects.
  • Alcohol: Use with alcohol is discouraged due to the risk of potentially fatal additive effects with the CNS-depressant component, Chlordiazepoxide.

Interaction-Related Restrictions and Contraindicated Conditions

Certain combinations or co-existing patient conditions are formally restricted or contraindicated based on regulatory labeling:

Classification Restricted Medicines/Conditions
Formally Contraindicated Glaucoma, Prostatic Hypertrophy, Benign Bladder Neck Obstruction
Contraindicated Known hypersensitivity to either Chlordiazepoxide or Clidinium Bromide

These constraints are due to the anticholinergic properties of Clidinium Bromide and the potential for exacerbating these conditions. Additionally, geriatric or debilitated patients are noted to be more susceptible to central effects such as oversedation or confusion, which increases the clinical significance of CNS-depressant interactions in this population.

Mechanism of Action

The final, E-E-A-T-optimized mechanistic text is presented below.

How Ulcedex Works

Ulcedex employs a dual pharmacodynamic mechanism by leveraging two active components that influence distinct physiological systems. The overall mechanism is achieved through the combined effects of central nervous system (CNS) modulation and peripheral gastrointestinal (GI) signaling alteration.


Modulating Central Nervous System Activity

Chlordiazepoxide, a benzodiazepine, acts as a positive allosteric modulator on GABAA receptors in the CNS. This interaction enhances the inhibitory conductance mediated by the neurotransmitter GABA, increasing the frequency of chloride channel opening. This engagement with the GABAergic signaling pathway increases neuronal inhibition, which results in decreased excitability in relevant neural circuits.


Regulating Peripheral Gastrointestinal Signaling

Clidinium Bromide, a synthetic anticholinergic agent, mediates the peripheral effect. It functions as an antagonist at muscarinic acetylcholine receptors, primarily M1, located on smooth muscle cells and secretory glands within the GI tract. Antagonism of these receptors suppresses cholinergic input, thereby altering smooth muscle tonus and decreasing glandular output within the gastrointestinal system.

Dosage and Administration Information

Administration Guidelines for Ulcedex

Ulcedex (Chlordiazepoxide/Clidinium Bromide) is administered orally, typically as a capsule or tablet. The proper use is determined by the specific dosing schedule and administration conditions outlined in the prescribing information.

Administration Detail Standard Instruction
Route & Form Oral route using the capsule or tablet dosage form.
Standard Adult Dosing 1 or 2 capsules (or tablets) administered three or four times per day.
Timing Constraint Must be taken approximately 30 to 60 minutes before meals and at bedtime.

Population-Specific Instructions

Certain patient groups require specific dose adjustments:

  • Elderly and Debilitated Patients: The initial dosage is limited to the smallest effective amount, generally not more than 2 capsules per day initially. The dose may be increased gradually as needed and tolerated.
  • Children: Use and dosage must be determined by a healthcare provider.

General Use Procedures

For administration, the medicine is to be taken with fluid. The dosage should always be individualized based on the patient's specific needs, adhering to the minimum effective dose and duration. A specific regimen for missed doses is not universally established; therefore, consult a professional for individualized guidance.

Adhering to these instructions—including the pre-meal timing and population-specific limits—is essential for following the usage protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ulcedex

Evidence for Use in Peptic Ulcer

Studies applied in research contexts involving fluctuating or unstable symptoms have explored how this medicine was evaluated in adult populations diagnosed with peptic ulcer disease. The medicine was studied for its role as an adjunctive therapy, meaning it was observed in patients who were also receiving primary anti-ulcer treatments. Research examined outcomes related to physical discomfort and outcomes monitoring physiological strain or stress associated with the condition.

Findings describe patterns observed in the studies related to the combination's adjunctive role in the observed populations. Findings help contextualize how patients reported their experience related to its two components for outcomes related to physical discomfort and outcomes monitoring physiological strain or stress associated with this condition. The evidence contributes to understanding symptom patterns, and regulatory documentation data show patterns related to the two components.

However, long-term effects are not fully established. Furthermore, the evidence contributes to understanding symptom patterns but provides limited insight into the isolated contribution of this specific combination when used alongside highly effective modern anti-ulcer medications.


Evidence for Use in Irritable Bowel Syndrome (IBS)

Short-term randomized controlled trials (RCTs) were conducted during periods of increased symptom activity and was studied for its application in conditions characterized by fluctuating or episodic manifestations like Irritable Bowel Syndrome (IBS). These studies included adults with symptomatic IBS. Researchers examined patient-reported outcomes describing perceived discomfort, specifically focusing on changes in abdominal pain, cramping, and overall symptom scores over defined time intervals.

Studies report how symptoms evolved in the observed populations and findings help contextualize how patients reported their experience during the study period. This evidence contributes to understanding symptom patterns related to outcomes linked to inflammatory or irritative states and the impact on outcomes reflecting daily functioning or activity level.

Evidence is limited information for long-term outcomes and the maintenance of measured outcomes beyond the short to medium term. The follow-up durations were limited in many of the core studies, and sample sizes were modest in some instances, meaning the results apply only to the populations studied and generalizability is uncertain.


Evidence in Special Populations

This part will outline the state of research regarding specific patient groups, detailing what studies (if any) have been conducted for older adults, and noting the absence of authorized clinical data for children.

Research Status in Older Adults

Research primarily evaluated in some studies outcomes monitoring physiological strain or stress including systemic or functional imbalance (e.g., oversedation or confusion) in older adults. Findings indicate that older adults may require different observation patterns related to dose. Due to this increased sensitivity, subgroup findings are uncertain when assessing typical outcomes.

Absence of Research in Children

Safety and efficacy studies have not been performed for the Ulcedex combination in pediatric patients (children <18 years of age). Therefore, data for certain groups remain insufficient, and regulatory summaries indicate an absence of authorized clinical evidence for this population.

Frequently Asked Questions (FAQ)

Common questions about Ulcedex (FAQ)

Q: How long does Ulcedex take to start working?

A: Regulatory information indicates that common effects on the central nervous system, such as drowsiness or sedation, may be most noticeable during the initial phase of treatment or when the dosage is increased. Official summaries typically do not detail a specific time frame for the onset of the medicine's intended therapeutic benefits.

Q: Is it normal to feel tired or dizzy after taking Ulcedex?

A: Regulatory documents state that drowsiness, sedation, dizziness, or loss of coordination (ataxia) are classified as common adverse reactions related to the nervous system. These effects are often reported during the initial phase of treatment.

Q: What happens if I stop taking Ulcedex suddenly?

A: Official documents caution that long-term use of Ulcedex carries a risk of physical dependence due to the benzodiazepine component. Abruptly stopping the medicine after prolonged use may be associated with the development of withdrawal symptoms.

Q: Can Ulcedex interact with common pain relievers like ibuprofen?

A: Official regulatory warnings focus primarily on Central Nervous System (CNS) depressants, such as opioids, due to the risk of additive effects. The core interaction warnings do not typically detail specific guidance for non-opioid pain relievers like ibuprofen.

Q: Can Ulcedex be taken with antacids?

A: The official administration guidelines recommend taking Ulcedex before meals, which is relevant to how antacids are often used. Regulatory information notes that compounds that affect stomach acidity (GI pH) could potentially alter how the medicine is absorbed, though a direct caution about antacids is not consistently present.

Q: Can Ulcedex be used by pregnant women?

A: Regulatory documentation notes that the medicine is generally avoided during the first trimester of pregnancy due to a documented potential risk of congenital malformations. Use in later pregnancy may also be associated with complications in the newborn, such as sedation.

Q: Can breastfeeding mothers use Ulcedex?

A: Regulatory summaries indicate that the potential benefits need to be weighed against potential risks to the infant, as there are often no adequate studies to fully assess infant risk when using the medicine during breastfeeding.

Q: Does Ulcedex affect liver function?

A: Official labeling identifies rare but serious adverse reactions, including signs of hepatic (liver) dysfunction or jaundice. For patients with pre-existing liver impairment, official documents require caution and close surveillance during treatment.

Q: What happens if I miss a dose of Ulcedex?

A: Because a specific, universal regimen for managing missed doses is not consistently published, regulatory documents suggest individualized guidance from a healthcare professional may be necessary.

Q: Is Ulcedex the same type of medicine as [similar common drug name]?

A: Ulcedex is described in official sources as a fixed-dose combination (FDC) synthetic drug. It is classified as a Psychotropic-Anticholinergic Combination, meaning it contains both a benzodiazepine (for central calming effects) and an antimuscarinic agent (for peripheral muscle relaxation).

Q: Why do doctors prescribe Ulcedex instead of other options?

A: The medicine is authorized as an adjunctive therapy, meaning it supports primary treatments for certain gastrointestinal disorders. Its dual-action structure is recognized for targeting both the emotional tension (anxiolytic effect) and the physical spasms (spasmolytic effect) that often complicate these conditions.

Q: How long does Ulcedex stay in your system?

A: The length of time the medicine stays in the body is determined by the elimination half-life of its active components. This technical information is detailed in the Clinical Pharmacology section of the official regulatory label.

Q: Can Ulcedex affect sleep?

A: Official regulatory documents list drowsiness and sedation as common adverse reactions. These effects on the central nervous system are noted to potentially affect sleep patterns.

Q: Are there different strengths or formulations of Ulcedex?

A: Official documents confirm that Ulcedex is available as a fixed-dose combination in capsule or tablet dosage forms. It is typically manufactured in one standard strength ratio of its two active ingredients.

Q: Can older adults use Ulcedex?

A: Yes, but official regulatory documents mandate caution when Ulcedex is used by older adults. They require a limited initial dosage because this population is noted to have increased sensitivity, which may raise the risk of side effects like confusion or oversedation.

Q: Does Ulcedex have a risk of dependence or addiction?

A: Official documentation explicitly notes that long-term use carries a documented risk of developing physical dependence associated with the benzodiazepine component, Chlordiazepoxide.

Q: Does Ulcedex interfere with birth control pills?

A: Regulatory information indicates that the primary known interactions involve Central Nervous System depressants and anticholinergic agents. The official label does not consistently contain a specific warning regarding interference with the effectiveness of hormonal contraceptives.

Q: Is Ulcedex available over the counter?

A: No. Due to the presence of the benzodiazepine component, Ulcedex is classified as a prescription-only medicine (Rx only) by the U.S. Food and Drug Administration (FDA) and similar national health authorities.

Q: Can Ulcedex be crushed or split?

A: Official administration instructions specify taking the capsule or tablet form orally with fluid. Unless the regulatory label specifically grants permission for the product to be altered, it is generally intended to be swallowed whole.

Q: Are there any foods I should avoid while on Ulcedex?

A: Official guidelines mandate that the medicine must be taken at a specific time relative to meals—approximately 30 to 60 minutes before meals and at bedtime. While specific food prohibitions are generally absent, proper timing around meals is considered essential for authorized usage.

Q: Does the effectiveness of Ulcedex change over time?

A: The clinical evidence summarized in regulatory documents is often drawn from short-term studies. The official safety and efficacy summaries note that the long-term effects and the maintenance of measured benefits over extended periods are limited.

Q: Does Ulcedex treat symptoms or the underlying condition?

A: The general purpose is to bring about symptomatic relief, specifically by stabilizing emotional and physical factors. It is authorized as an 'adjunctive therapy,' meaning its role is to support and be used alongside primary treatments.

Q: Is Ulcedex a controlled substance?

A: Yes, due to its benzodiazepine component (Chlordiazepoxide), the medicine is classified as a Schedule IV controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent national bodies.

Q: Why do some people need to adjust their Ulcedex dose?

A: Official labeling mandates specific dose adjustments, particularly for patient groups who may be more sensitive to the medicine's effects, such as older adults and debilitated patients. This is done to prevent adverse effects like oversedation and confusion.

Q: Does Ulcedex cause problems with vision?

A: Official safety documentation lists 'blurred vision' as a common anticholinergic side effect. Furthermore, the medicine is strictly prohibited (contraindicated) for patients diagnosed with angle-closure glaucoma.

Q: How quickly do side effects from Ulcedex usually appear?

A: The common central nervous system effects, such as drowsiness, are officially noted to be most prominent during the initial phase of treatment or shortly following a dosage increase.

Q: Is Ulcedex intended for prevention or relief?

A: The medicine is authorized for symptomatic relief and is described as an adjunctive therapy, meaning its primary role is to help reduce existing symptoms.

Q: Does Ulcedex change the way other medicines are absorbed?

A: The regulatory documents detail the pharmacokinetics (how the body processes the drug) and metabolism of the components. This information, found in the Clinical Pharmacology section, may describe effects on certain metabolic enzymes that could alter how other medicines are processed and absorbed.

How should Ulcedex be stored and disposed of?

How to Store and Dispose of Ulcedex?

The storage and handling of Ulcedex (chlordiazepoxide and clidinium bromide) must adhere strictly to regulatory specifications to ensure product integrity and public safety.


Storage Requirements

  • Temperature: Store the medication at a controlled room temperature, specifically between 20 C and 25 C.
  • Protection: The product must be protected from light and stored away from excess moisture and heat. Keep the medication in the container it came in, ensuring the container is tightly closed.
  • Child Safety: It is a mandatory requirement to store Ulcedex in a safe place, ensuring it is kept out of the sight and reach of children and pets.

Disposal Instructions

Expired or unused medication must not be kept. Official guidance recommends disposing of Ulcedex through a drug take-back program or pharmacy-led collection service. If no take-back program is available, the product should be mixed with an unappealing substance, sealed in a bag, and then placed in the household trash; disposal via wastewater is restricted.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcedex found in:

A-Z Index: